Immune-priming of the Tumor Microenvironment by Radiotherapy: Rationale for Combination With Immunotherapy to Improve Anticancer Efficacy
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
A clear contribution of the immune system to eradication of tumors has been supported by recent developments in the field of immunotherapy. Durable clinical responses obtained after treatment with immunomodulatory agents such as ipilimumab (Yervoy) and anti-PD-1 antibody (BMS-936558), have established that harnessing the immune response against chemoresistant tumors can result in their complete eradication. However, only a subset of patients benefit from these therapeutic approaches. Accumulating evidence suggests that tumors with a preexisting active immune microenvironment might have a better response to immunotherapy. In a number of preclinical and clinical studies, many cytotoxic agents elicit changes within tumors and their microenvironment that may make these malignant cells more sensitive to an efficient immune cell attack. Therefore, it is plausible that combining immunotherapy with standard anticancer therapies such as chemotherapy or radiotherapy will provide synergistic antitumor effects. Despite a large collection of preclinical data, the immune mechanisms that might contribute to the efficacy of conventional cytotoxic therapies and their combinations with immunotherapeutic approaches have not yet been extensively studied in the clinical setting and warrant further investigation. This review will focus on current knowledge of the immunomodulatory effects of one such cytotoxic treatment, radiotherapy, and explore different pathways by which its combination with immunomodulatory antibodies might contribute toward more efficacious antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“There was a significant survival advantage in patients treated with the combination rather than dacarbazine alone.(4) The changes in the immune profiles of patients treated with RT and immunotherapy with consequent abscopal effect was described recently and is yet another example of how harnessing the immune system mi…”
BackgroundSelf-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 5×
“47 In addition, CRT complexes with MHC-1-b2m to promote antigen presentation,48 and its exposure serves to send an “eat me signal” to DCs.9,49 CRT translocation plays a major role in the phagocytosis of dying cells by antigen presenting cells (ie, DCs) as its neutralization by blocking agents such as siRNA can complet…”
BackgroundResultInfluentialApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 3×
“Extracellular HMGB1 binds to toll-like receptor 4 on DCs that emits signals that promote their antigen processing and presentation to T cells.(8) Adenosine triphosphate released by apoptotic cells, on the other hand, is required to engage the purinoreceptor P2RX7, which induces secretion of interleukin (IL)-1b through…”
BackgroundResultCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“However, CTLA-4 has greater binding affinity for CD80/CD86 than CD28 and therefore, upon its surface translocation, it binds to CD80/CD86 more avidly, blocking the interaction between CD28 and its ligands.(76,77) Although deactivation of T cells by CTLA-4 may be a normal physiological phenomenon that avoids an overly…”
BackgroundGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 3×
“In preclinical tumor models, infiltration of tumors by both IL-17 producing gd T cells and IFN-g secreting effector T cells were found to be required for tumor regression by cytotoxic agents.(36,37,44) Furthermore, gd T cells express NKG2D on their surface,(40) whose ligand is upregulated when tumors are exposed to RT…”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678 · cited 3×
“Interestingly, in B16/C57BL6 murine melanoma tumor model, ablative RT was shown to generate CD8 + T-cell–mediated responses, whereas fractionated RT elicited a reverse effect by causing immunosuppression and subsequent increase in relapse over time.21 In this in vivo tumor model, activation of CD8 + T cells was mediat…”
BackgroundResultLee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., Beckett, M., Sharma, R., Chin, R., Tu, T., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206870 · Cited by 1,324
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 1×
“Binding of PD-1 to its ligands, PD-L1 or PD-L2 results in the recruitment of phosphatases to the immunologic synapse and subsequent dephosphorylation of proximal T-cell antigen receptor signaling molecules.(90) Although both CTLA-4 and PD1 exert immune-regulatory effects on T cells, there are subtle differences betwee…”
Backgroundvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 1×
“Despite its clear clinical activity in human melanoma as monotherapy, CTLA-4 blockade alone has shown minimal effects in preclinical models of poorly immunogenic tumors such as the murine B16F10 model, unless it is combined with other therapeutic modalities.(69,79,83) This suggests that in poorly immunogenic tumors, p…”
BackgroundLugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 1×
“In the B16/OVA melanoma tumor model, localized tumor irradiation was found to increase surface expression of MHC-1 molecules on tumor cells and VCAM-1 on intratumoral vasculature endothelium; both events depended on the secretion of IFN-g by the infiltrating T cells.(24,25) The VCAM-1 protein mediates the adhesion of…”
BackgroundQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“In contrast, combining CTLA-4 blockade with another immunostimulatory factor such as GM-CSF shifted the ratio of T effector cells to regulatory T cells, resulting in more efficacious antitumor immunity.(80,84) Further evidence comes from studies described above where combination of CTLA-4 blocking antibody synergized…”
BackgroundObeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W. W., Lizée, G., Radvanyi, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1187 · Cited by 432
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Ecto‐calreticulin in immunogenic chemotherapy
Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., Van Endert, P., Ghiringhelli, F., Apetoh, L., Chaput, N., Flament, C., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00567.x · Cited by 202 · cited 1×
“Another particular consequence of immunogenic cell death by RT is the translocation of calreticulin (CRT) and Erp57 from the endoplasmic reticulum to the plasma membrane in the dying tumor cells.(18) CRT is a calcium-binding chaperonin related to the family of heat shock proteins.”
Background
Cited by
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Lan, G., Tang, H., Pelizzari, C., Fu, Y.-X., Spiotto, M. T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0203-4 · Cited by 596
Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b09538 · Cited by 458
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Ni, K., Lan, G., Chan, C., Quigley, B., Lu, K., Aung, T., Guo, N., La Riviere, P., Weichselbaum, R. R., & Lin, W. (2018) · Nature Communications · doi:10.1038/s41467-018-04703-w · Cited by 336
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Faje, A. (2016) · Pituitary · doi:10.1007/s11102-015-0671-4 · Cited by 326
Metadata
- Authors
- Shahabi, V., Postow, M. A., Tuck, D., & Wolchok, J. D.
- Venue
- American Journal of Clinical Oncology
- Published
- 2015-02
- Volume
- 38
- Issue
- 1
- Pages
- 90-97
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W2324532698
- Cited by
- 86
- References
- 18
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.